Frédéric Stauffer

TL;DR: The preclinical data show that NVP-BEZ235 is a potent dual PI3K/mTOR modulator with favorable pharmaceutical properties, and the compound was well tolerated, displayed disease stasis when administered orally, and enhanced the efficacy of other anticancer agents when used in in vivo combination studies.

TL;DR: In this paper, the use of organic compounds of formula (I) processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof -alone or in combination with one or more other pharmaceutically active compounds -for treatment of an inflammatory or obstructive airway disease, such as asthma, disorders commonly occurring in connection with transplantation, or a proliferative disease such as a tumor disease.

TL;DR: T tumor vasculature reduction was correlated with full blockade of endothelial nitric oxide (NO) synthase, a PI3K/Akt-dependent but mTORC1-independent effector involved in tumor permeability through NO production, and early reduction of permeability, as detected using the dynamic contrast-enhanced magnetic resonance imaging contrasting agent P792, was found to be a predictive marker for late-stage antitumor activity by NVP-BEZ235.

TL;DR: The present mini-review provides an update on new PI3K inhibitors currently in or entering clinical development and discusses recent discoveries, challenges and future prospects.

TL;DR: In this article, NVP-BEZ235, a series of dual PI3K/mammalian target of rapamycin (mTOR) inhibitors, was used to attenuate melanoma growth.